Topic: psoriasis


9. Tremfya

Johnson & Johnson's Tremfya was the first selective IL-23 inhibitor to land on the scene.

6. Skyrizi

Despite multiple drugs working through inhibiting inflammatory interleukins, AbbVie's Skyrizi is still carving out a meaningful share.

10. Stelara

Johnson & Johnson's stalwart immunology blockbuster Stelara has been a steady earner for years. But with some areas of its portfolio lagging behind, J&J is hoping that pushing Stelara into new markets can help overcome those stumbles—and keep Stelara generating significant sales for years to come.